Switching from Reference to Biosimilar Filgrastim in Pediatric Patients


( Last Updated : June 2, 2021)
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1575-000

Details


Question

1. What is the clinical effectiveness of switching from reference to biosimilar filgrastim in pediatric patients?
2. What is the comparative clinical effectiveness of biosimilar Nivestym versus biologic Neupogen for pediatric patients?

Key Message

No relevant literature was identified regarding the clinical effectiveness of switching from reference to biosimilar filgrastim in pediatric patients. No relevant literature was identified regarding the comparative clinical effectiveness of biosimilar Nivestym versus biologic Neupogen for pediatric patients.